Loading resource…

Emma M Groarke, Benjamin Turturice, Bhavisha A Patel, Kaitlin A Quinn, Alice Fike, Peter C Grayson
VEXAS syndrome is a recently identified monogenic disease affecting older men, characterized by severe systemic inflammation and progressive bone marrow failure due to mutations in the UBA1 gene. The review discusses the clinical features, epidemiology, and potential treatment options, including glucocorticoids and emerging therapies like JAK inhibitors and hypomethylating agents. It emphasizes the complexity of managing this condition and the need for further research into effective therapies.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

Myeloproliferative Neoplasms
Same clinical topic · Hematology

MASTOCYTOSIS
Same clinical topic · Hematology

MYELODYSPLASTIC SYNDROMES: 2023 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT
Same clinical topic · Hematology

PERIPHERAL T-CELL LYMPHOMAS
Same clinical topic · Hematology

COMPARISON OF THE INTERNATIONAL CONSENSUS AND 5TH WHO EDITION CLASSIFICATIONS OF ADULT MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Same clinical topic · Hematology

IRON DEFICIENCY
Same clinical topic · Hematology

MULTIPLE MYELOMA: 2026 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION AND MANAGEMENT
Same clinical topic · Hematology

ANTIDOTES FOR ANTICOAGULATION REVERSAL
Same clinical topic · Hematology

POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND ANTHYMOCTE GLOBULIN IN 8/10 HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATION
Same clinical topic · Hematology